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Selective Induction of DNA Synthesis in
Mouse Preneoplastic and Neoplastic Hepatic
Lesions after Exposure to Phenobarbital
by James E. Klaunig
Recent evidence has suggested that the induction ofDNAsynthesis by nongenotoxic chemical
carcinogens plays an important role in the formation of cancer. The present study examined
the effect of a nongenotoxic carcinogen, phenobarbital, (PB) on the induction ofDNA synthesis
in preneoplastic foci and adenomas in B6C3F1 mice. Male mice were treated with diethylni-
trosamine at 30 days of age. After 6 months, mice had both hepatic foci and adenomas. Mice
were divided into three groups at random and treated with PB in the drinking water and exam-
ined for DNA labeling by autoradiography. Before sacrifice, each mouse received an osmotic
minipump containing [3H] thymidine. Results showed a PB dose-dependent increase in DNA
synthesis in hepatic foci. Adenomas were unresponsive to the DNA synthesis-enhancing effect
ofPB, maintaining a level of 20-25%. The nornal surrounding liver showed an increase in DNA
synthesis (10-15% labeling index) at the 7-day sampling, which returned to normal control lev-
els by 28 and 45 days. The foci showed a heterogeneity in response, with some foci showing an
increase (20-30o labeling index), and others maintaining control DNA synthesis levels (4-6%
labeling index). These results show that preneoplastic foci in the mouse respond preferentially
to the induction of DNA synthesis by PB, that this response is dose dependent, and that it is
maintained as long as the treatment continues.
Introduction
The development of liver cancer in rodents after
exposure to chemical carcinogens is a multistep
process (1-3). In the liver, at least three stages, initia-
tion, promotion, and progression, have been identified
using biochemical and morphological markers. DNA
synthesis and cell proliferation are important in each of
these stages. During the initiation stage, a single liver
cell is genotypically modified. Cell proliferation is nec-
essary in this stage to lock in this mutational change.
The stage of tumor promotion involves the selective
clonal expansion of the initiated cell to a focal group of
cells. This change appears to be reversible and is histo-
logically represented in the liver by the hepatic focal
areas of cellular alteration [focus (4)]. The progression
stage also involves a genotoxic, mutational event. In
the liver, the progression stage is represented histo-
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logically by the appearance of neoplastic lesions (ade-
nomas and carcinomas). Cell proliferation is necessary
for the expansion and growth of the neoplastic lesions
(1-5).
A number of chemical carcinogens appear to induce
hepatic tumors in rodents through nongenotoxic mech-
anisms. The mechanism(s) by which these compounds
induce cancer in the liver of rodents remains unre-
solved. Nongenotoxic carcinogens are generally nega-
tive in short-term genotoxicity, mutation, and cell
transformation assays. What is apparent is that the
nongenotoxic hepatic carcinogens exhibit a number of
similar cellular changes in the rodent liver after expo-
sure. These include induction of mixed-function oxi-
dase enzymes including P450, inhibition of gap junc-
tional intercellular communication, induction of
hepatocyte DNA synthesis, and induction of hepato-
cyte cell proliferation. These latter two parameters
have recently received extensive attention. Two possi-
ble mechanisms by which the induction of DNA syn-
thesis and cell proliferation by these nongenotoxic car-
cinogens may induce hepatic cancer have been put
forth (6). In one scenario, the induction ofhepatic DNA
synthesis has been proposed to produce genetic muta-
tion through the upsetting of normal DNA synthesis
and replication. One of three fates can beset theseJ. E. KLAUNIG
mutated cells: the DNA damage is repaired, the muta-
tion is incompatible with life and cell death occurs, or
the mutation is not repaired, producing an initiated
cell. In the latter outcome, the initiated cell then has
the potential to progress through the stages ofhepatic
tumorigenesis, eventually resulting in aneoplasm.
In a second scenario, the liver already contains a
number ofinitiated cells (either spontaneously induced
or from exposure to an initiating agent) that require
the additional events to allow these cells to progress to
the neoplastic stage. In this case, exposure to a non-
genotoxic carcinogen may result in the selective prolif-
eration and clonal expansion ofthe initiated cells. This
would result in the formation of hepatic foci with the
possibility of some of the foci progressing to hepatic
adenomas and carcinomas. This selective induction of
DNA synthesis by the nongenotoxic carcinogen may
be the result of differences in the preneoplastic cell
that allow for the increased proliferative response, an
inhibition ofDNA synthesis in the normal surrounding
liver, or a combination of both effects. In the current
study, the role that cell proliferation may play in this
second scenario was investigated in the mouse liver
after exposure to the nongenotoxic carcinogen pheno-
barbital.
Methods
Male B6C3F1 mice were used in this study. Mice
were purchased from Charles River Breeding Labor-
atories at 21 days of age. After 7 days of acclimation,
mice were treated with a single IP injection ofdiethyl-
nitrosamine (DEN) at 30 days ofage (90 mg/kg BW (7).
Mice were then maintained on Purina Lab Blox and
deionized water ad libitum for 36 weeks. At 36 weeks,
mice were randomly divided into four groups of 12
mice each. Group 1 received 500 mg/L ofphenobarbital
in their drinking water; group 2 received 100 mg/L
phenobarbital in their drinking water; group 3
received 20 mg/L of phenobarbital in their drinking
water; and group 4 received 0 mg/L ofphenobarbital in
their drinking water. Mice were treated with pheno-
barbital for 7, 14, 28, and 45 days. Three mice from
each group were sacrificed at each time period. Seven
days before sacrifice, each mouse received an osmotic
minipump containing [3H] thymidine (8). At sacrifice,
livers were weighed and processed for histology.
Paraffin-embedded liver from each mouse was sec-
tioned, processed for autoradiography, and stained
with hematoxylin and eosin. The labeling index for
hepatic foci, adenomas, and normal surrounding liver
was determined by counting the number of labeled
hepatocytes (7,8). In foci and adenomas, all ofthe hepa-
tocytes within the lesion on the histological section
were scored for DNA synthesis. In the normal sur-
rounding liver, randomly selected areas of 50 cells
were scored. Hepatic foci were histologically grouped
as a class, and unique tinctorial characteristics (i.e.,
basophilic, eosinophilic, clear cell) were not used to dif-
ferentiate the foci because previous studies have
shown that mouse liver foci treated with phenobarbital
tend to express the eosinophilic phenotype during the
phenobarbital treatment. A total of 50 foci, 25 adeno-
mas, and 1500 normal, surrounding hepatocytes were
quantitated for labeling index from the three mice for
each sampling group and sampling time. Labeling
index values were statistically compared by Fisher's
Exact test (7,8).
Results
The normal, surrounding liver showed a dose-depen-
dent increase in DNA synthesis at the 7-day and 14-
day sampling times, which returned to levels of
untreated controls by the 28-day sampling time. (Fig.
1). Hepatocytes from untreated control mice showed
an average labeling index of 4-5% at each of the four
sampling times. The induction of DNA synthesis by
phenobarbital in the normal, surrounding hepatocytes
was dose dependent. Treatment with 500 mg/L pheno-
barbital in the drinking water produced a labeling
index of 19.4% after 7 days and 22.5% after 14 days,
whereas treatment with 100 mg/L phenobarbital
resulted in a labeling index of 14.4% after 7 days and
12.3% after 14 days. Treatment with 20 mg/L pheno-
barbital did not increase the labeling index over that of
the untreated control.
A dose-dependent increase in DNA synthesis as
measured by labeling index was also seen in hepatic
foci from phenobarbital-treated mice (Fig. 2). Foci
from untreated mice showed an average labeling index
of 17.2% at the 7-, 14-, 28-, and 45-day sampling times.
Treatment with 500 mg/L phenobarbital resulted in a
significant increase in labeling index above the
untreated control values. The labeling index in these
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FIGURE 1. Labeling index in normal hepatocytes after treatment of
B6C3FW male mice with phenobarbital at concentrations of 0, 20,
100 and 500 mg/L in the drinking water for 7, 14, 28, and 45 days.
Three mice at each phenobarbital concentration were sampled at
each time, and the labeling index was determined by autoradiog-
raphy. A minimum of 500 cells were scored for each mouse.
(*)Values significantly greater than the untreated control (p <
0.05).
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FIGURE 2. Labeling index in hepatocytes in foci after treatment of
B6C3F, male mice with phenobarbital at concentrations of 0, 20,
100, and 500 mg/L in the drinking water for 7, 14, 28, and 45 days.
Liver lesions were induced in the mice by treatment with a single
dose of diethylnitrosamine at 30 days or age 36 weeks before
treatment with the phenobarbital. Three mice at each phenobarbi-
tal concentration were sampled at each time, and the labeling
index was determined by autoradiography. A minimum of50 focal
lesions were scored for the three mice. All cells in each focal lesion
were scored. (*) Values significantly greater than the untreated
control (p < 0.05).
foci averaged 32.5% labeling for the 7-, 14-, 28-, and 45-
day sampling times. Unlike the normal surrounding
hepatocytes, the labeling index in the foci treated with
500 mg/L phenobarbital remained at a significantly
increased level during the entire treatment period
(Fig. 2). Treatment with 100 mg/L also produced a sus-
tained increase in labeling index throughout the expo-
sure period. The labeling index for the 100 mg/L treat-
ment averaged 26.7% for the four sampling times (Fig.
2). This increase was significantly increased over con-
trol values and significantly lower than the labeling
index values seen for the 500 mg/L treatment. Treat-
ment of mice with 20 mg/L did not induce an increase
in labeling index over the untreated control values at
any ofthe times sampled (Fig. 2).
The DNA induction effect ofphenobarbital in hepat-
ic foci displayed a heterogeneous pattern of response
(Fig. 3). When hepatic foci treated with 500 mg/L of
phenobarbital were grouped based on their labeling
index, it became apparent that not all of the hepatic
foci responded to the phenobarbital effect on DNA
synthesis in a similar manner. In untreated control
mice (not receiving phenobarbital), the foci labeling
index in more than 70% of the foci examined was 25%
or less (Fig. 3). After treatment with phenobarbital for
7 days, a shift in the pattern of the labeled foci was
seen, with over 50% of the foci exhibiting a labeling
index of 26% or greater. These results suggest that
there are several populations of hepatic foci with
regard to DNA synthetic inductive response to pheno-
barbital.
Adenomas from mice treated with phenobarbital
were unresponsive to the DNA synthetic-enhancing
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FIGURE 3. Labeling index in hepatic foci receiving either no pheno-
barbital or 500 mg/L phenobarbital for 7 days. Liver lesions were
induced in the mice by treatment with a single dose ofdiethylnitro-
samine at 30 days ofage 36 weeks before treatment with the phe-
nobarbital.
effects of this drug (Fig. 4). Adenomas showed a con-
stant labeling index ranging from 21.4%-25.7% at all of
the doses and sampling times of phenobarbital treat-
ment.
Discussion
These results show that preneoplastic foci in the
mouse respond preferentially when compared to nor-
mal hepatocytes to the induction of DNA synthesis by
phenobarbital. This response is dose dependent, with
the two highest doses of phenobarbital (500 mg/L and
100 mg/L) producing an increase in labeling index, and
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FIGURE 4. Labeling index in hepatocytes in adenomas after treat-
ment of B6C3Fj male mice with phenobarbital at concentrations
of0, 20, 100, and 500 mg/L in the drinking water for 7, 14, 28, and
45 days. Liver lesions were induced in the mice by treatment with
a single dose of diethylnitrosamine at 30 days of age 36 weeks
before treatment with the phenobarbital. Three mice at each phe-
nobarbital concentration were sampled at each time, and the
labeling index was determined by autoradiography. A minimum of
25 adenomatous lesions were scored for the three mice. All cells in
each adenoma were scored. (*) Values significantly greater than
the untreated control (p < 0.05).
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the lowest dose (20 mg/L) having no effect on the label-
ing index. This shows a correlation to the dose -
response effect ofphenobarbital with regard to hepatic
cancer induction in mice. Treatment ofmice with doses
above 100 mg/L produced a significant increase in
hepatic tumors in the mice. Studies of chronic treat-
ment with phenobarbital at doses of20 mg/L and lower
have not been performed on mice. Therefore, a dose-
response correlation between the selective induction of
hepatic DNA synthesis by phenobarbital in the focal
lesions and the induction of hepatic cancer has not
been confirmed (9,10).
Based on these preliminary results, it appears that
the hepatic foci uniquely respond to the DNA synthe-
sis inductive effects of phenobarbital compared to the
normal, surrounding hepatocytes and the adenomatous
hepatocytes. Although the normal, surrounding hepa-
tocytes showed a temporal dose-response increase in
labeling index at the two highest doses studied, this
labeling index returned to control levels after the 14-
day treatment period. The hepatic foci showed a dose-
responsive increase in labeling that remained elevated
for the entire duration of the phenobarbital exposure.
In contrast, the hepatic adenomas were refractory to
the DNA synthesis inductive effects of phenobarbital
at all the phenobarbital doses examined. It appears
from these data that the adenoma stage ofhepatic can-
cer may have been refractory to the effects of the
nongenotoxic carcinogen (in this case phenobarbital).
The mechanism for the observed selective DNA syn-
thesis response ofthe foci to phenobarbital remains to
be resolved. It may be the result of intrinsic differ-
ences in the preneoplastic focal cell that allow for the
increased response to phenobarbital. These intrinsic
differences could be the result of differences in
response to growth factors (14,15), hormones (such as
the glucocorticoids), or metabolism of the phenobarbi-
tal. It should be emphasized that in the present study
the cell proliferative rate and cell death rate in the
hepatic lesions were not quantitated. Previous studies
in the rat have shown that modulation ofthe cell death
rate in hepatic lesions plays an important role in the
selective cell proliferative-enhancing effect of pheno-
barbital on the hepatic foci (16). However, contrary to
the results in the present study in the mouse, Schulte-
Hermann et al. (17) showed that in the rat liver, pheno-
barbital increased cell growth but not through an
increase in DNA synthesis. These workers noted that
the increase was through a selective decrease in cell
death rate in the hepatic foci. Whether this species dif-
ference in the effect of phenobarbital on focal lesion
DNA synthesis is species dependent or protocol
dependent remains unanswered. Attempts to quanti-
tate the rate ofapoptosis in the mouse liver lesions has
proven difficult. Therefore, the effects of phenobarbi-
tal on focal lesion cell death rate and normal, surround-
ing hepatocyte death rate (measured by apoptosis)
remains to be quantitated (17).
Studies on the mechanisms ofwhy the preneoplastic
foci display a selective response to phenobarbital
remain to be performed. The system used in the pre-
sent study provides us with a valuable model for exam-
ining the effects ofextrinsic and intrinsic agents on the
DNA synthesis and growth of hepatic tumors. This
model may be ofvalue in examining both growth stim-
ulatory and growth inhibitory effects ofvarious agents
on hepatic preneoplastic and neoplastic lesions.
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